Apert syndrome
MONDO:0007041Apert syndrome (AS) is a frequent form of acrocephalosyndactyly, a group of inherited congenital malformation disorders, characterized by craniosynostosis, midface hypoplasia, and finger and toe anomalies and/or syndactyly.
Also known as: ACS1, Apert syndrome, acrocephalosyndactyly type 1, acrocephalosyndactyly type I, type I Acrocephalosyndactyly, ACS 1, ACS 2, Apert-Crouzon disease
12 clinical trials for this condition and its sub-types, 11 tagged with Apert syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Apert syndrome
-
Maroteaux Fonfria syndrome 0 trials
-
Nano-ink gel could replace repeated skull surgeries for kids with rare genetic disorders
Disease control Recruiting nowThis early-stage study aims to develop a personalized treatment for children with syndromic craniosynostosis, a group of rare genetic disorders where skull bones fuse too early. The approach uses a nano-engineered gel to deliver custom genetic medicine directly to the affected ar…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
Disease control Recruiting nowThis phase 3 trial tests whether a combination of two experimental drugs (futibatinib and zimberelimab) plus standard chemotherapy can help people with advanced biliary tract cancer live longer compared to current standard immunotherapy combinations. The study enrolls about 784 a…
Phase 3 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New antibody targets FGFR1 to fight metastatic cancers
Disease control Recruiting nowThis study tests a new drug called OM-RCA-01, an antibody that blocks a protein called FGFR1 found on some cancer cells. About 58 adults with metastatic kidney, lung, prostate, breast, or head and neck cancers that express FGFR1 will receive the drug by IV every two weeks. The go…
Phase 1/2 • Sponsor: Kidney Cancer Research Bureau • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New pill targets rare cancer gene in last-resort patients
Disease control Recruiting nowThis study tests an experimental drug called E7090 in people with advanced or returning solid tumors that have a specific change in the FGFR gene. About 75 participants will receive the drug to see if it can shrink tumors and control the disease. The goal is to offer a new option…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC